Raymond James Initiates Coverage On LENZ Therapeutics with Outperform Rating, Announces Price Target of $37

Benzinga · 09/27 17:09
Raymond James analyst Gary Nachman initiates coverage on LENZ Therapeutics (NASDAQ:LENZ) with a Outperform rating and announces Price Target of $37.